-
-
-
-
-
-
-
SCYNEXIS receives FDA designations for antifungal drug SCY-247
-
-
-
-
-
-
-
Scynexis (SCYX) resumes dosing in Phase 3 study of ibrexafungerp
-
-
-
-
-
456,387 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

